Drospirenone

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Drospirenone
    1. Pharmacist Assessment Report
    2. Drospirenone: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Drospirenone: Known uses and market status in Australia

Summary

All of the model’s candidates for Drospirenone that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use is recorded as a relation in the knowledge graph and is not backed by an approval found in our data.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 1
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
acne (disease)

Australia Market Information

Licence Product Dosage form Status
14791L Slinda Pack containing 24 tablets 4 mg and 4 in Valid

Safety Considerations

Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.

The following items come from a knowledge graph (not label text) and should be verified against the PI.

  • Conditions flagged as contraindications in the knowledge graph include hypertensive disorders, epilepsy, anxiety and neurotic disorders, porphyria, kidney disease, liver disease, gallbladder disease, adrenocortical insufficiency (Addison disease), hypothyroidism, systemic lupus erythematosus, asthma, diabetes mellitus (including diabetic ketoacidosis), hypertriglyceridemia, and hypercalcemia-related conditions.
  • Drug interactions: 100 interactions were identified, and the main ones are listed below.
    • Major: clarithromycin.
    • Moderate: antidiabetic agents (for example acarbose, albiglutide, alogliptin, canagliflozin, dapagliflozin, empagliflozin, exenatide, glimepiride, glipizide, glyburide), aprepitant, acetylsalicylic acid, potassium citrate and clotrimazole.

Because drospirenone has antimineralocorticoid activity, potassium and renal function would be relevant to any new use. This should be confirmed against the PI.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.